Cargando…

Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfected patients

BACKGROUND AND AIM: Hepatitis C virus (HCV) therapy should be considered without delay in all patients with significant (SIGFIB) or advanced liver fibrosis (ADVFIB). We aimed to investigate the rates of treatment initiation with interferon-free regimens within a screening program for SIGFIB/ADVFIB i...

Descripción completa

Detalles Bibliográficos
Autores principales: Chromy, David, Schwabl, Philipp, Bucsics, Theresa, Scheiner, Bernhard, Strassl, Robert, Mayer, Florian, Aichelburg, Maximilian C., Grabmeier-Pfistershammer, Katharina, Trauner, Michael, Peck-Radosavljevic, Markus, Reiberger, Thomas, Mandorfer, Mattias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5816107/
https://www.ncbi.nlm.nih.gov/pubmed/28744597
http://dx.doi.org/10.1007/s00508-017-1231-x
_version_ 1783300619439702016
author Chromy, David
Schwabl, Philipp
Bucsics, Theresa
Scheiner, Bernhard
Strassl, Robert
Mayer, Florian
Aichelburg, Maximilian C.
Grabmeier-Pfistershammer, Katharina
Trauner, Michael
Peck-Radosavljevic, Markus
Reiberger, Thomas
Mandorfer, Mattias
author_facet Chromy, David
Schwabl, Philipp
Bucsics, Theresa
Scheiner, Bernhard
Strassl, Robert
Mayer, Florian
Aichelburg, Maximilian C.
Grabmeier-Pfistershammer, Katharina
Trauner, Michael
Peck-Radosavljevic, Markus
Reiberger, Thomas
Mandorfer, Mattias
author_sort Chromy, David
collection PubMed
description BACKGROUND AND AIM: Hepatitis C virus (HCV) therapy should be considered without delay in all patients with significant (SIGFIB) or advanced liver fibrosis (ADVFIB). We aimed to investigate the rates of treatment initiation with interferon-free regimens within a screening program for SIGFIB/ADVFIB in human immunodeficiency virus/HCV coinfected patients (HIV/HCV). METHODS: The FIB-4 was calculated in all HIV/HCV from 2014–2016. HIV/HCV were counselled by the HIV clinic and referred to the Division of Gastroenterology and Hepatology for transient elastography (TE) and evaluation for HCV therapy. Patients were stratified by FIB-4 of </≥1.45 (established cut-off for ruling out ADVFIB) and SIGFIB/ADVFIB were defined by liver stiffness >7.1 kPa/>9.5 kPa, respectively. RESULTS: Among 1348 HIV+ patients, 16% (210/1348) had detectable HCV-RNA. One hundred HIV/HCV had a FIB-4 ≥1.45. Among these, 57% (57/100) underwent TE. The majority of these patients had SIGFIB (75%; 43/57) or ADVFIB (37%; 21/57), however, interferon-free treatment was initiated in only 56% (24/43). In addition, fifty-two percent (57/110) of HIV/HCV with FIB-4 <1.45 underwent TE. Interestingly, 40% (23/57) and 18% (10/57) of these patients showed SIGFIB or even ADVFIB, respectively, and 78% (18/23) finally received interferon-free treatment. Overall, only 20% (42/210) of HIV/HCV received interferon-free treatment. CONCLUSION: FIB-4 was not useful for ruling out SIGFIB/ADVFIB in our cohort of HIV/HCV. Treatment was initiated only in a small proportion (20%) of HIV/HCV during the first 2 years of interferon-free treatment availability, although the observed proportion of patients with SIGFIB (assessed by TE) was considerably higher (58%). Thus, it requires the ongoing combined efforts of both HIV and HCV specialists to increase treatment uptake rates in this special population. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi: 10.1007/s00508-017-1231-x) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5816107
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Vienna
record_format MEDLINE/PubMed
spelling pubmed-58161072018-02-27 Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfected patients Chromy, David Schwabl, Philipp Bucsics, Theresa Scheiner, Bernhard Strassl, Robert Mayer, Florian Aichelburg, Maximilian C. Grabmeier-Pfistershammer, Katharina Trauner, Michael Peck-Radosavljevic, Markus Reiberger, Thomas Mandorfer, Mattias Wien Klin Wochenschr Original Article BACKGROUND AND AIM: Hepatitis C virus (HCV) therapy should be considered without delay in all patients with significant (SIGFIB) or advanced liver fibrosis (ADVFIB). We aimed to investigate the rates of treatment initiation with interferon-free regimens within a screening program for SIGFIB/ADVFIB in human immunodeficiency virus/HCV coinfected patients (HIV/HCV). METHODS: The FIB-4 was calculated in all HIV/HCV from 2014–2016. HIV/HCV were counselled by the HIV clinic and referred to the Division of Gastroenterology and Hepatology for transient elastography (TE) and evaluation for HCV therapy. Patients were stratified by FIB-4 of </≥1.45 (established cut-off for ruling out ADVFIB) and SIGFIB/ADVFIB were defined by liver stiffness >7.1 kPa/>9.5 kPa, respectively. RESULTS: Among 1348 HIV+ patients, 16% (210/1348) had detectable HCV-RNA. One hundred HIV/HCV had a FIB-4 ≥1.45. Among these, 57% (57/100) underwent TE. The majority of these patients had SIGFIB (75%; 43/57) or ADVFIB (37%; 21/57), however, interferon-free treatment was initiated in only 56% (24/43). In addition, fifty-two percent (57/110) of HIV/HCV with FIB-4 <1.45 underwent TE. Interestingly, 40% (23/57) and 18% (10/57) of these patients showed SIGFIB or even ADVFIB, respectively, and 78% (18/23) finally received interferon-free treatment. Overall, only 20% (42/210) of HIV/HCV received interferon-free treatment. CONCLUSION: FIB-4 was not useful for ruling out SIGFIB/ADVFIB in our cohort of HIV/HCV. Treatment was initiated only in a small proportion (20%) of HIV/HCV during the first 2 years of interferon-free treatment availability, although the observed proportion of patients with SIGFIB (assessed by TE) was considerably higher (58%). Thus, it requires the ongoing combined efforts of both HIV and HCV specialists to increase treatment uptake rates in this special population. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi: 10.1007/s00508-017-1231-x) contains supplementary material, which is available to authorized users. Springer Vienna 2017-07-25 2018 /pmc/articles/PMC5816107/ /pubmed/28744597 http://dx.doi.org/10.1007/s00508-017-1231-x Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Chromy, David
Schwabl, Philipp
Bucsics, Theresa
Scheiner, Bernhard
Strassl, Robert
Mayer, Florian
Aichelburg, Maximilian C.
Grabmeier-Pfistershammer, Katharina
Trauner, Michael
Peck-Radosavljevic, Markus
Reiberger, Thomas
Mandorfer, Mattias
Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfected patients
title Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfected patients
title_full Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfected patients
title_fullStr Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfected patients
title_full_unstemmed Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfected patients
title_short Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfected patients
title_sort non-invasive liver fibrosis assessment and hcv treatment initiation within a systematic screening program in hiv/hcv coinfected patients
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5816107/
https://www.ncbi.nlm.nih.gov/pubmed/28744597
http://dx.doi.org/10.1007/s00508-017-1231-x
work_keys_str_mv AT chromydavid noninvasiveliverfibrosisassessmentandhcvtreatmentinitiationwithinasystematicscreeningprograminhivhcvcoinfectedpatients
AT schwablphilipp noninvasiveliverfibrosisassessmentandhcvtreatmentinitiationwithinasystematicscreeningprograminhivhcvcoinfectedpatients
AT bucsicstheresa noninvasiveliverfibrosisassessmentandhcvtreatmentinitiationwithinasystematicscreeningprograminhivhcvcoinfectedpatients
AT scheinerbernhard noninvasiveliverfibrosisassessmentandhcvtreatmentinitiationwithinasystematicscreeningprograminhivhcvcoinfectedpatients
AT strasslrobert noninvasiveliverfibrosisassessmentandhcvtreatmentinitiationwithinasystematicscreeningprograminhivhcvcoinfectedpatients
AT mayerflorian noninvasiveliverfibrosisassessmentandhcvtreatmentinitiationwithinasystematicscreeningprograminhivhcvcoinfectedpatients
AT aichelburgmaximilianc noninvasiveliverfibrosisassessmentandhcvtreatmentinitiationwithinasystematicscreeningprograminhivhcvcoinfectedpatients
AT grabmeierpfistershammerkatharina noninvasiveliverfibrosisassessmentandhcvtreatmentinitiationwithinasystematicscreeningprograminhivhcvcoinfectedpatients
AT traunermichael noninvasiveliverfibrosisassessmentandhcvtreatmentinitiationwithinasystematicscreeningprograminhivhcvcoinfectedpatients
AT peckradosavljevicmarkus noninvasiveliverfibrosisassessmentandhcvtreatmentinitiationwithinasystematicscreeningprograminhivhcvcoinfectedpatients
AT reibergerthomas noninvasiveliverfibrosisassessmentandhcvtreatmentinitiationwithinasystematicscreeningprograminhivhcvcoinfectedpatients
AT mandorfermattias noninvasiveliverfibrosisassessmentandhcvtreatmentinitiationwithinasystematicscreeningprograminhivhcvcoinfectedpatients